Načítá se...

Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: A single institutional experience

PURPOSE: The objectives of this study were to evaluate the effectiveness of nab-paclitaxel plus gemcitabine (NAB-P/GEM) regimen in an unselected population of patients with advanced inoperable or metastatic pancreatic cancer (PC), and to identify the prognostic factors influencing overall survival (...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Lo Re, Giovanni, Santeufemia, Davide A., Foltran, Luisa, Bidoli, Ettore, Basso, Stefano M.M., Lumachi, Franco
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2015
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4480749/
https://ncbi.nlm.nih.gov/pubmed/25779664
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!